Untranslated

86-21-64556180

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
FAQs
Contact Us

Home
Products
Featured Products

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
- DPP-4
- SGLT-1
- SGLT-2
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

Featured Products

Abediterol napadisylate; LAS100977 napadisylate
4-((4-(3-morpholinopropoxy)phenyl)ethynyl)aniline
Vorolanib; CM-082; X-82
AZD0022
GSK4418959; IDE275
RMC-5127
BMS-986449
RO7656594; GDC-2992
AMG 410
Topoisomerase I inhibitor 8
CU CPT 9a
Revefenacin; TD 4208; GSK1160724; Yupelri
Zasocitinib; NDI 034858; TAK 279
KSQ4279; RO7623066
navlimetostatum; navlimetostat; MRTX 1719; BMS ...
Pirtobrutinib; LOXO 305; LY 3527727
BAY 293
BAY 985
Olinciguat; IW 1701
Elimusertib; BAY 1895344
methyl 4-((tert-butoxycarbonyl)(prop-2-yn-1-yl)...
ML 265; CID 44246499; NCGC 00186528; TEPP 46
1-Azetidinesulfonamide(9CI)
Omaveloxolone; RTA 408
Tuxobertinib; BDTX-189
Bavdegalutamide; ARV 110
Resmetirom; MGL3196; VIA 3196
Ropotrectinib; TPX 0005
Avapritinib; BLU 285
(4-(4-Methylthiazol-5-yl)phenyl)methanamine hyd...

1 2 3 4 5 6 Next > >> Page 1 / 17

Contact Us

3rd Floor, Building 4, 3918 Daye Road, Fengxian District, Shanghai
86-21-64556180
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

ARS-1620: A promising new inhibitor for KRAS-mutant cancers

ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

prev

next

© Copyright - 2010-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !

TOP

Previous Maximize